Scarica l'app Stockscreener
29.60
0.82%
0.24
Dopo l'orario di chiusura:
29.61
0.010
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$29.36
Aprire:
$29.06
Volume 24 ore:
2.35M
Relative Volume:
1.05
Capitalizzazione di mercato:
$4.89B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
15.18
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+5.79%
1M Prestazione:
+0.65%
6M Prestazione:
+0.75%
1 anno Prestazione:
+4.15%
Intervallo 1D:
$29.06
$30.08
Intervallo di 1 settimana:
$27.50
$30.08
Portata 52W:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.60 | 4.85B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
What dividend safety score for Alkermes plc stockMarket Sentiment Review & High Yield Equity Trading Tips - ulpravda.ru
Will Alkermes plc stock split attract more investorsJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
Is Alkermes plc stock supported by innovation pipelineGold Moves & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Alkermes plc stock a good choice for value investors2025 Trading Volume Trends & Free Technical Confirmation Trade Alerts - ulpravda.ru
How FDA Breakthrough Therapy Status for Alixorexton Will Impact Alkermes (ALKS) Investors - simplywall.st
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Finviz
Alkermes plc's (NASDAQ:ALKS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Yahoo Finance
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - Sleep Review
Is Alkermes plc (8AK) stock a top pick for value investors2026 world cup usa national team round of 16 goalkeepers set piece tactics knockout prediction expert opinion - ulpravda.ru
Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance UK
Alkermes to present at the 44th annual JP Morgan Healthcare Conference - MSN
FDA Grants Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1 - HCP Live
Alkermes stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Alkermes stock rises after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Alkermes’ narcolepsy drug By Investing.com - Investing.com South Africa
Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug - TipRanks
Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 - Business Wire
Alkermes Plc (ALKS) Stock Analysis: Unveiling A 55% Upside Potential For Investors - DirectorsTalk Interviews
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013 - AOL.com
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock - MarketBeat
J.P. Morgan Healthcare Conference - marketscreener.com
Levels Update: Will Alkermes plc 8AK stock outperform global peersChart Signals & Short-Term Trading Alerts - moha.gov.vn
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.04 Million in Alkermes plc $ALKS - MarketBeat
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Centessa narcolepsy data not superior to Alkermes, says Stifel - MSN
Trading the Move, Not the Narrative: (ALKS) Edition - Stock Traders Daily
Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS - MarketBeat
About the Alkermes Inspiration Grants® Program - CSRwire
Alkermes plc (ALKS) Stock Price History & Data - Traders Union
Why Analysts are Rating Alkermes (ALKS) a Buy - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Alkermes plc stock positioned for digital transformation2025 Market Outlook & Weekly Breakout Watchlists - Улправда
Will Alkermes plc stock benefit from commodity pricesTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
Why global investors buy Alkermes plc (8AK) stockEarnings Recap Report & Reliable Volume Spike Alerts - Bölüm Sonu Canavarı
ALKS (Alkermes) Other Current Payables : $0 Mil (As of Sep. 2025) - GuruFocus
Will Alkermes plc (8AK) stock test record highs in 20252025 Performance Recap & Low Risk Growth Stock Ideas - DonanımHaber
Can Alkermes plc stock continue upward trendPortfolio Gains Summary & Comprehensive Market Scan Reports - DonanımHaber
Behavioral Patterns of ALKS and Institutional Flows - Stock Traders Daily
Is Alkermes plc (8AK) stock a momentum leaderTrade Risk Assessment & Real-Time Stock Entry Alerts - Улправда
How Alkermes plc (8AK) stock reacts to monetary easingBear Alert & Free Reliable Trade Execution Plans - Улправда
Alkermes (STU:8AK) OCF Margin % : 25.79% (As of Sep. 2025) - GuruFocus
BlackRock increases stake in Alkermes to 17.04% - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView — Track All Markets
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.41%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):